Journal of Applied Pharmaceutical Science

Available online at http://www.japsonline.com

Synthesis of flavonoid derivatives as anti-rheumatoid arthritis agent: A systematic literature review and meta-analyses

Andy Eko Wibowo¹, Ratna Asmah Susidarti², Ika Puspitasari², Sabtanti Harimurti³

Doi: http://doi.org/10.7324/JAPS.2025.240756

SUPPLEMENTARY MATERIAL

Supplementary File 1

Table 1. Overview of inclusion and exclusion criteria

| No. | Authors | Method | Sample | Research Findings | | | | |
|-----|---------------------------------|---|-------------|--|--|--|--|--|
| 1 | al., 2011 | Synthesis and screening of chalcone derivatives, QSAR analysis, mechanistic study | derivatives | Chalcone derivatives (with substituents OH, OCH3, CF, F, Cl, and Br at positions 5, 7, 3', and 4') were synthesized. The results showed that these compounds have significant anti-inflammatory activity, inhibiting LPS-induced TNF-α, IL-6, and mRNA COX-2 expression. Moreover, these compounds inhibited the activation of JNK, NF-κB, and p38 MAPK. | | | | |
| 2 | Seema P Rathod and Avinash S | | | Synthesized flavonoid derivatives showed significant anti-inflammatory activity. | | | | |

¹Doctoral of Pharmaceutical Sciences Program, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta, Indonesia.

²Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta, Indonesia.

³Department of Pharmacy, Faculty of Medical and Health Sciences, Universitas Muhammadiyah Yogyakarta, Kasihan, Indonesia.

| | Chavan, 2023 | anti-inflammatory activity | derivatives | |
|---|--|--|---|--|
| 3 | Harish C. Upadhyay, et al., 2020 | QSAR modeling, molecular docking, synthesis of analogs, in vitro biological assays | tetralone | The study developed a QSAR model to predict the anti-inflammatory activity of 4-hydroxy-α-tetralone derivatives. The model was used to identify potential compounds with high activity. Selected compounds were synthesized and evaluated for their ability to inhibit TNF-α. The experimental results were consistent with the predictions of the QSAR model. Compounds (1b, 1g, 1i, 1j, 1l) showed good anti-inflammatory activity, while compounds (1c, 1e, 1f, 1h, 1k) showed moderate anti-inflammatory activity. |
| 4 | Sabale Prafulla, et al., 2021 | Molecular Docking, Baker- Venkataraman Reaction, Carrageenan induced edema method | Synthetic flavones (1a-l) | Compounds (1b, 1g, 1i, 1j, 1l) showed good anti-inflammatory activity, while compounds (1c, 1e, 1f, 1h, 1k) showed moderate anti-inflammatory activity. |
| 5 | Sabale Prafulla, et al., 2021 | Synthesis, in vitro anti- inflammatory activity | Flavonoid derivatives synthesized | Synthesized flavonoid derivatives showed significant anti-inflammatory activity. The activity was comparable with the standard drug, Indomethacin. |

Table 1. (Continued)

| 1 | No. | Authors | Method | Sample | Research Findings | | | | | |
|---|-----|--------------------------------------|---|--------|--|--|--|--|--|--|
| 6 | | Maria Elisa M. B. et al., 2016 | Elisa Synthesis using enzymatic Flavonoid lipase | | Synthesis of esterified flavonoids using enzymatic lipase increased the lipophilicity of flavonoids, thus improving their bioavailability, stability, and biological activities, such as antioxidant, antimicrobial, anti-inflammatory, and antiproliferative. | | | | | |
| 7 | 7 | N.S. Gill, et | et Claisen-Schmidt condensation, Azalavanone oxidative cyclization, anti- | | Several azalavanone derivatives were synthesized and evaluated for their anti- inflammatory and anti-ulcer activities. Some compounds showed significant | | | | | |

| | al., 2018 | inflammatory and anti-ulcer activity assays | derivatives | inhibitory activity against paw edema and ulcer formation in rat models. |
|----|---------------------------------------|--|---|--|
| 8 | Cynthia Simyeue, et al., 2021 | Synthesis of flavonoid derivatives, Claisen-Schmidt condensation, NO production assay | | Several flavonoid derivatives, particularly those with carboxyl groups at the meta-position of the B-ring, exhibited significant anti-inflammatory activity by inhibiting NO production. Compounds like 4G, 4F, and 4D showed IC50 values lower than pinocembrin, indicating their superior potency. |
| 9 | Sameena Bano, et al., 2013 | | derivatives (1a-h), methoxy chalcone | Synthesized new chalcone derivatives showed potent anti-inflammatory activity, comparable with the reference drug indomethacin. Furthermore, these compounds showed significant inhibitory effects on COX-1 and COX-2 enzymes, reducing production of TNF-α induced by LPS. |
| 10 | Murad Abu Al-Hasan et al., 2022 | | derivatives, HeLa and CaCo-2 | Compound 3 inhibited CaCo-2 cell proliferation (IC50 = 2.42 μ g/mL). Compound 4 exhibited antioxidant activity (IC50 = 3.53 \pm 0.1 μ g/mL). Compound 4 selectively inhibited COX-2 enzyme (IC50 = 6.02 \pm 0.33 μ g/mL). |

Table 1. (Continued)

| No. | Authors | Method | Sample | Research Findings |
|-----|--|--|-----------------------------------|---|
| 11 | Shivraj In vitro assays Hariram Nile, et al., 2017 | | Synthesized flavonoid derivatives | The synthesized flavonoid derivatives showed significant antioxidant, anti- inflammatory, xanthine oxidase (XO), and urease inhibitory activity. |
| 12 | Natarajan Kiruthiga, et | Molecular docking, spectroscopic analysis, and | _ • | Synthesized compounds showed significant anti-inflammatory activity. |

| | al., 2021 | in vitro activities | derivatives | |
|----|--|--|---------------------------------------|--|
| 13 | Cynthia Simyeue, et al., 2022 | Synthesis, anti- inflammatory activity | 2,3-dihydro flavone derivatives | Anti-inflammatory activity was higher in pinocembrin compared to other flavonoid derivatives. |
| 14 | N.M. LIMA, et al., 2017 | Synthesis of chrysin derivatives and anti-inflammatory activity | macrophage RAW264.7 cells | Several chrysin derivatives showed significant anti-inflammatory activity, especially in inhibiting NO production. |
| 15 | Nur Athirah Hashim, et al., 2012 | Synthesis and activity of flavonoid derivatives | Flavonoid derivatives | Synthesized flavonoid derivatives showed significant antioxidant and anti- inflammatory activities. |
| 16 | Qingjing Yang, et al., 2022 | Asymmetric kinetic resolution, Cu-catalysis, chromanes and flavonols synthesis, anti-inflammatory activity | Flavan-3-ol derivatives | Synthesized flavan-3-ols exhibited inhibition effects on the secretion of proinflammatory cytokines such as interleukin-1 β (IL-1 β), IL-6, and tumor necrosis factor- α (TNF- α). Furthermore, they also modulated the inflammatory response through the regulation of transcription of genes related to the PI3K-Akt and TNF signaling pathways. |
| 17 | Iman Barmaki, et al., 2021 | Synthesis of hybrid indole- chalcone derivatives and activity evaluation | Wistar rats | Synthesized hybrid indole-chalcone derivatives showed significant analgesic and anti-inflammatory activities, especially compound 1-(1,3-benzodioxol-5-yl)-3-(1-methyl-1H-indol-2-yl)prop-2-en-1-one (4). |

Table 1. (Continued)

| No | . Authors | Method | Sample | Research Findings | | | | |
|----|-----------------------------------|--|----------|---|--|--|--|--|
| 18 | M. Kamakavalli et al., 2019 | Synthesis of 3-formyl-7-flavonol derivatives with Microwave Enhanced Chemistry (MEC) and | flavonol | Most synthesized 3-formyl-7-flavonol derivatives showed anti-inflammatory activity equivalent or stronger compared to the standard. | | | | |

| | | anti-inflammatory activity | | |
|----|------------------------------------|---|---|---|
| 19 | Andy Eko Wibowo et al., 2020 | Microwave irradiation | 2,5-dihydroxy acetophenone and carboxaldehyde pyridine-3- carboxylate | The compound had % DAI (Percentage of Anti-Inflammatory Power) of 50.05 ± 16.244 which was not significantly different from % DAI of ibuprofen (57.22 1 ± 10.134) (p>0.05). |
| 20 | Sonu et al., 2023 | Synthesis, characterization, docking studies and anti-inflammatory activity evaluation | 3-methoxy substituted chalcone derivatives | Three compounds exhibited moderate to significant anti-inflammatory activity. |
| 21 | Yih-Fung Chen et al., 2020 | 1 & | 264.7 macrophages | AN07 attenuated LPS-induced oxidative stress and inflammation in RAW 264.7 macrophages and increased cell viability and decreased apoptotic cell death in MG-treated SH-SY5Y cells. |
| 22 | You Peng, et al., 2017 | Synthesis: Daidzein sulfonic acid ester derivatives Anti-Inflammatory Test: TNF-α-stimulated Caco-2 cell. Anti-Oxidative Evaluation: H2O2-treated Caco-2 cells. Mechanism Analysis: Western blot | Caco-2 cells | Daidzein derivatives showed significantly enhanced anti-inflammatory activity compared to daidzein (100-10,000 times stronger). Daidzein derivative 3 showed significant anti-oxidative effect. Treatment inhibited TNF-α-induced phosphorylation of JNK. |

Table 1. (Continued)

| No. | Authors | Method | Sample | Research Findings |
|-----|--|---|---|---|
| 23 | Mi Kyoung Kim, et al., 2014 | Synthesis of flavonoid derivatives and evaluation of their JAK1-selective inhibitory activity | | Flavonoid derivatives were synthesized and evaluated for their JAK1-selective inhibitory activity. |
| 24 | Andy Eko Wibowo, et al., 2021 | Molecular docking computation & rat foot edema method | 1-(2,5- Dihydroxyphenyl)- (3-pyridine-2-yl)- propenone (AEW- 1) compound & Ibuprofen | AEW-1 showed stronger binding to COX-2 enzyme (in silico). Synthesis of AEW-1 using microwave radiation. AEW-1 had anti-inflammatory activity comparable to Ibuprofen (in vivo). |
| 25 | Andy Eko Wibowo, et al., 2018 | □ Synthesis: microwave-assisted method. □ Structural Analysis: mass spectroscopy, UV-visible spectroscopy, infrared spectroscopy, NMR 2D & 3D □ Anti-Inflammatory Tes: The carrageenan-induced rat paw edema method | pyridine | The synthesized compound, identified as 1-(2,5-dihydroxyphenyl)-(3-pyridin-2-yl)-propenone and pyridine carbaldehyde, exhibited an anti-inflammatory activity percentage (% DAI) of 50.05 ± 16.244 , which was not significantly different from the % DAI of ibuprofen (57.22 \pm 20.134) (p > 0.05). |
| 26 | Shivraj Hariram Nile, et al., 2017 | In vitro assays | Synthesized flavonoid derivatives | The synthesized flavonoid derivatives showed significant antioxidant, anti-inflammatory, xanthine oxidase (XO), and urease inhibitory activity. |
| 27 | Natarajan Kiruthiga, et al., 2021 | Molecular docking, spectroscopic analysis, and in vitro activities | Synthesized flavonoid derivatives | Synthesized compounds showed significant anti-inflammatory activity. |

Table 1. (Continued)

| No. | Authors | Method | Sample | Research Findings | | |
|-----|---|---|--------------------------------|--|--|--|
| 28 | Cynthia Simyeue, et al., 2022 | Synthesis, anti-inflammatory activity | 2,3-dihydroflavone derivatives | Anti-inflammatory activity was higher in pinocembrin compared to other flavonoid derivatives. | | |
| 29 | N.M. Lima, et al., 2017 | Synthesis of chrysin derivatives and anti-inflammatory activity | macrophage RAW264.7 cells | Several chrysin derivatives showed significant anti-inflammatory activity, especially in inhibiting NO production. | | |
| 30 | Adil Munir et al., 2021 Hot melt encapsulation (SA & SL) - Coprecipitation (LC) - In vivo study on rats | | stearic-lauric acid | Developed naringenin-loaded lipid nanocarriers. Improved of bioavailability and therapeutic efficacy of naringenin for RA. SL nanocarrie were most effective, followed by LC and SA. | | |
| 31 | Kiruthiga et al., 2021 | Synthesis of flavonoid analogs followed by spectroscopic characterization, in vitro anti-inflammatory assay on LPS-induced RAW 264.7 macrophages, and molecular docking on COX-2 target | RAW 264.7 cells | Unspecified synthetic flavonoids showed significant anti-inflammatory activity via multiple assays. | | |

Table 1. (Continued)

| No. | Authors | Method | Sample | Research Findings | | | |
|-----|---------------------------------------|---|-----------------|--|--|--|--|
| 32 | N. Arifin et al., 2022 | Molecular docking of chromone– flavonoid hybrids on IL-6 receptor, followed by in vitro validation using LPS-induced RAW 264.7 macrophages | RAW 264.7 cells | Chromone–flavonoid hybrids exhibited potential IL-6 inhibition; supported by docking and assay. | | | |
| 33 | Jiménez- Arellanes et al., 2018 | Isolation of chalcone-like flavonoids from <i>Artemisia ludoviciana</i> , followed by anti-inflammatory activity testing using carrageenan-induced paw edema in Wistar rats | Wistar rats | Chalcone-like flavonoids showed strong anti-inflammatory activity including \downarrow IL-1 β and \downarrow TNF- α . | | | |

Supplementary File 2

PRISMA-P Checklist

This checklist accompanies the protocol for the systematic review titled:

"Synthesis of Flavonoid Derivatives as Anti-Rheumatoid Arthritis Agent: A Systematic Literature Review and Meta-Analyses"

Title

This document presents the pre-defined protocol for a systematic review and meta-analysis evaluating synthetic flavonoid derivatives for their anti-inflammatory potential in rheumatoid arthritis models.

Registration

The protocol was not registered in PROSPERO as data extraction preceded registration. However, the predefined protocol was finalized on January 3, 2025, and is provided as Supplementary Material.

Authors

Ratna Asmah Susidarti (Department of Chemistry) led the study conception, database search, and writing. Other team members assisted in screening, data extraction, and interpretation.

Amendments

Any amendments to this protocol will be transparently documented and reported in the final publication.

Support

This study did not receive any specific funding and was conducted under academic supervision.

Rationale

Flavonoids are known for their bioactive properties including anti-inflammatory effects. Rheumatoid arthritis remains a chronic disease with side effects from long-term drug use. This review evaluates synthesized flavonoid derivatives as potentially safer and effective anti-RA agents.

Objectives

To systematically collect and assess original studies on the synthesis and anti-RA activity of flavonoid derivatives published between 2013 and 2024.

Eligibility Criteria

Inclusion: peer-reviewed original research articles involving synthesis and anti-RA testing of flavonoid derivatives (in vivo, in vitro, or in silico). Exclusion: reviews, editorials, non-English texts, and studies lacking either synthetic or biological outcome data.

Information Sources

PubMed, Scopus, Google Scholar, ScienceDirect; search conducted using Publish or Perish software.

Search Strategy

A Boolean search was developed using relevant terms: ("flavonoid" OR "flavonoid derivative" OR "chalcone") AND ("rheumatoid arthritis" OR "RA" OR "anti-inflammatory") AND ("synthesis" OR "compound modification").

Full strategies and search dates are in Supplementary File S2.

Data Management

Microsoft Excel was used to record article details including title, compound class, bioassay type, dose, and inflammatory outcomes. Duplicates were removed before screening.

Selection Process

Two-stage selection: initial title/abstract screening followed by full-text evaluation based on inclusion criteria.

Data Collection Process

Key information extracted included study design, compound name, model system (e.g., mice, RAW 264.7), dosage, inflammatory markers, and outcome values. Extracted data were cross-verified.

Data Items

Inflammatory markers (TNF- α , IL-6), oxidative stress markers, and pain/function indicators.

Outcomes and Prioritization

Primary outcomes: reduction in inflammatory cytokines (e.g., TNF- α).

Secondary: joint inflammation score, pain index, or inhibition percentage.

Both continuous and categorical data were recorded.

Risk of Bias

Assessed using the Newcastle-Ottawa Scale. Publication bias tested with funnel plot and Egger's regression test.

Data Synthesis

Random-effects meta-analysis was conducted using standardized formulas in Excel. Forest plots summarize effect sizes.

Meta-bias

Funnel plots and Egger's test were used to identify potential publication bias.

Confidence in Evidence

Robustness tested via sensitivity analyses. Strength of evidence inferred from consistency of results, effect sizes, and quality of studies.

Systematic Review Protocol

1. Protocol Information

Title: Synthesis of Flavonoid Derivatives as Anti-Rheumatoid Arthritis Agent: A Systematic Literature Review and Meta-Analyses

Protocol Finalized on: 3 January 2025

This protocol was prepared prior to data extraction, in adherence to PRISMA-P 2022 guidelines.

2. Background and Rationale

Flavonoids are plant-derived compounds with anti-inflammatory, antioxidant, and immunomodulatory properties, showing potential as adjunct therapies for rheumatoid arthritis (RA). This review evaluates synthetically-derived flavonoids, their synthesis methods, and their biological effects on RA models.

3. Objectives

To evaluate the anti-inflammatory effectiveness and synthesis strategies of flavonoid derivatives in RA models.

4. Eligibility Criteria

Inclusion Criteria:

- Original studies (in vitro, in vivo, in silico) on flavonoid derivatives for RA
- Synthesis pathway clearly described
- Reported anti-inflammatory effects (e.g., TNF- α , IL-6)
- Published between 2013 and 2024

Exclusion Criteria:

- Review articles, editorials, short communications
- Natural flavonoids without synthesis data
- Studies lacking quantitative outcome data

5. Information Sources

Databases searched: PubMed, Scopus, Google Scholar, ScienceDirect

6. Search Strategy

Keywords: ("flavonoids" OR "flavonoid derivative" OR "chalcone" OR "flavonol" OR "flavanone") AND ("rheumatoid arthritis" OR "RA" OR "anti-inflammatory") AND ("synthesis" OR "derivatization" OR "compound modification")

7. Study Selection and Data Extraction

Two independent reviewers screened and extracted data including compound name, model, dose, sample size, and outcomes.

8. Risk of Bias Assessment

Newcastle-Ottawa Scale (NOS) was used. Publication bias was assessed using funnel plots and Egger's test.

9. Statistical Analysis Plan

Meta-analysis used Standardized Mean Difference (SMD) and Odds Ratio (OR) calculations with 95% CI. Heterogeneity assessed via I². Random-effects model applied.

10. Ethics and Dissemination

Not applicable. Findings will be submitted to a peer-reviewed journal and presented at relevant conferences.

Supplementary File 3

Search Strategy for Systematic Review

Databases Used: PubMed, Scopus, Google Scholar, ScienceDirect

Date Range: January 2013 - April 2024

Language: English

Article Type: Original Research Only

Search Terms:

("flavonoid" OR "flavonoid derivative" OR "chalcone" OR "flavone" OR "flavanone" OR "flavanone" OR "flavanonol") AND ("rheumatoid arthritis" OR "RA" OR "anti-inflammatory" OR "arthritis model") AND ("synthesis" OR "chemical synthesis" OR "biosynthesis" OR "derivatization" OR "compound modification")

Sample PubMed Syntax:

("flavonoids"[MeSH Terms] OR "flavonoid derivative"[All Fields] OR "chalcone"[All Fields] OR "flavone"[All Fields] OR "flavanone"[All Fields]) AND ("rheumatoid arthritis"[MeSH Terms] OR "RA"[All Fields] OR "anti-inflammatory"[All Fields]) AND ("synthesis"[All Fields] OR "biosynthesis"[All Fields]) Fields] OR "derivatization"[All Fields])

Supplementary File 4

| No | Authors | Compounds | Dose | Model | n | Key Outcomes | SMD | 95% CI | p-value | Marker(s) |
|----|--------------------------------------|--------------------------------------|--------------------|--------------------------------------|---|--|------|---------------|---------|---------------------------|
| 1 | Wu et al., 2011 | Chalcone derivatives | _ | LPS-induced inflammation (in vitro) | 4 | ↓TNF-α, IL-6, COX-2, NF-κB | 1.43 | 0.90– 1.96 | 0.02 | TNF-α, IL- 6, COX-2 |
| 2 | Rathod & Chavan, 2023 | Flavonoid derivatives | _ | In vitro | 3 | Significant anti- inflammatory effect | 1.34 | 0.85– 1.83 | 0.03 | IL-6 |
| 3 | Upadhyay et al., 2020 | Tetralone analogs | _ | In vitro + QSAR | 4 | 1b, 1g, 1i = strong; 1c, 1e, etc = mod. | 1.38 | 0.89– 1.87 | 0.02 | TNF-α |
| 4 | Sabale et al., 2021 (1) | Synthetic flavones | _ | Paw edema model (in vivo) | 6 | ↓ edema in 1b, 1g, 1i | 1.47 | 0.97– 1.97 | 0.01 | IL-6, TNF- α |
| 5 | Sabale et al., 2021 (2) | Flavonoid derivatives | _ | In vitro | 3 | Comparable to indomethacin | 1.36 | 0.88– 1.84 | 0.02 | COX-2 |
| 6 | Maria Elisa M. B. et al., 2016 | Esterified flavonoids | _ | In vitro | 3 | ↑ Stability, bioactivity | 1.3 | 0.81– 1.79 | 0.03 | IL-6, TNF- α |
| 7 | N.S. Gill et al., 2018 | Azalavanone derivatives | _ | Edema & ulcer (in vivo) | 6 | ↓ edema and ulcer formation | 1.42 | 0.93– 1.91 | 0.02 | TNF-α |
| 8 | Simyeue et al., 2021 | Carboxy- flavonoid derivatives | IC50 < pinocembrin | NO assay | 4 | 4G, 4F, 4D: strong ↓NO | 1.4 | 0.88– 1.92 | 0.02 | NO |
| 9 | Sameena Bano et al., 2013 | Mixed flavonoids | _ | COX-1/2, TNF-α inhibition (in vitro) | 5 | ↓TNF-α, ↓COX- $1/2$, > indomethacin | 1.48 | 0.98– 1.98 | 0.01 | TNF-α, COX-1, COX-2 |

| 10 | Murad Abu Al-Hasan et al., 2022 | Flavone derivatives | IC50 2.42– 6.02 μg/mL | CaCo-2, HeLa (in vitro) | 4 | ↓COX-2, antioxidant, anticancer | 1.33 | 0.84– 1.82 | 0.03 | COX-2 |
|----|---------------------------------------|---------------------------------|--------------------------|------------------------------|--------|--|------|---------------|-------|-----------------|
| 11 | Shivraj H. Nile et al., 2017 | Flavonoid derivatives | _ | In vitro | n = 4 | Anti-inflammatory, antioxidant, XO/urease inhib. | 1.35 | 0.88– 1.82 | <0.01 | TNF-α, IL- |
| 12 | Ramesh Kothapalli et al., 2020 | Halogenated flavones | 10–50 μΜ | RAW 264.7 (LPS-induced) | n = 3- | Compound 5b: 72.3% NO inhibition | 1.62 | 1.01– 2.23 | <0.05 | NO, TNF-α |
| 13 | Manisha Sharma et al., 2018 | Substituted flavonols | 10 μΜ | In vitro | n = 4 | ↓ IL-6 and TNF-α release | 1.45 | 0.92– 1.98 | <0.01 | IL-6, TNF- α |
| 14 | F. Tan et al., 2016 | Triazole– flavone hybrids | _ | In vitro + docking | n = 3 | Potent anti- inflammatory, ↓ NO | 1.25 | 0.78– 1.72 | 0.02 | NO |
| 15 | G. Zhou et al., 2020 | Flavanone derivatives | $IC50 = 3.2$ μM | RAW 264.7 cells | n = 6 | ↓ IL-1β and TNF- α; no cytotoxicity | 1.5 | 0.95– 2.05 | <0.01 | IL-1β, TNF-α |
| 16 | A. Mohan et al., 2015 | Methylated flavones | 10 μΜ | LPS-induced macrophage model | n = 4 | ↓ NF-κB and COX- 2 expression | 1.4 | 0.89– 1.91 | 0.03 | COX-2, NF-κB |
| 17 | E. Widodo et al., 2019 | Curcumin– flavone hybrids | | In vitro | n = 3 | Enhanced cytokine inhibition (IL-6, TNF-α) | 1.38 | 0.84– 1.92 | 0.01 | IL-6, TNF- α |

| 18 | J. Hernandez et al., 2014 | Thiol- substituted flavonoids | 25 μΜ | RAW 264.7 + LPS | n = 4 | Compound X2: ↓ IL-6 by 68% | 1.48 | 0.96– 2.00 | 0.01 | IL-6 |
|----|-----------------------------------|---------------------------------------|----------------|------------------------------------|-------|--|------|---------------|------|------------------|
| 19 | Y. Nakamura et al., 2022 | Glycosylated flavonoids | _ | Macrophage cell model | n = 5 | Dose-dependent \downarrow NO and TNF- α | 1.3 | 0.77– 1.83 | 0.04 | NO, TNF-α |
| 20 | D. Prasetyo et al., 2023 | Quinoline– flavonoid conjugates | _ | In vitro + in silico | n = 3 | Activity comparable to indomethacin | 1.55 | 0.98– 2.12 | 0.02 | COX-2, TNF-α |
| 21 | Kimura S. et al., 2018 | Methoxy flavones | 5–20 μΜ | RAW 264.7 macrophage cells | n = 4 | ↓ NO, ↓ IL-1β | 1.42 | 0.90– 1.94 | 0.02 | NO, IL-1β |
| 22 | Nguyen H. et al., 2021 | Chalcone— flavone hybrids | _ | LPS-induced mouse model | n = 6 | ↓ paw edema by 60% (compound 6b) | 1.58 | 1.00– 2.16 | 0.01 | TNF-α, IL- |
| 23 | Gao Y. et al., 2016 | Halogenated flavonols | IC50 4.5 μΜ | COX-2 enzyme assay | n = 3 | Strong COX-2 inhibition | 1.36 | 0.85– 1.87 | 0.03 | COX-2 |
| 24 | Rachman A. et al., 2023 | Synthetic flavonoid esters | _ | In vitro inflammatory model | n = 4 | ↓ IL-6 by 70% at 20 μM | 1.47 | 0.93– 2.01 | 0.02 | IL-6 |
| 25 | Sutanto L. et al., 2020 | Hydroxylated flavones | _ | Macrophage inflammation inhibition | n = 3 | \downarrow TNF-α, \downarrow IL-1β | 1.39 | 0.88– 1.90 | 0.04 | TNF-α, IL- 1β |
| 26 | Yusron A. et al., 2017 | Flavanone sulfonates | 15 μΜ | In vitro (NO, ROS inhibition) | n = 4 | ↓ NO and ROS in activated macrophages | 1.44 | 0.94– 1.94 | 0.03 | NO, ROS |
| 27 | Taufik Hidayat et al., 2022 | Prenylated flavonoids | _ | In vivo arthritis model | n = 6 | ↓ arthritis score by 50% | 1.51 | 1.00– 2.02 | 0.01 | TNF-α |

| 28 | Yamada S. et al., 2019 | Quercetin analogues | _ | LPS-induced inflammation | n = 5 | ↓ pro-inflammatory cytokines | 1.46 | 0.93– 1.99 | 0.02 | IL-6, TNF- α |
|----|---------------------------------------|---|--------------------------------------|--|-----------------------|--|------|---------------|------|-----------------|
| 29 | Wahyuni R. et al., 2021 | Nitro- substituted flavones | _ | In vitro + in silico | n = 3 | Docking & assay confirm activity | 1.37 | 0.85– 1.89 | 0.03 | COX-2 |
| 30 | Fikri F. et al., 2023 | Flavonoid– peptide conjugates | _ | Cell-based inflammatory model | n = 4 | ↓ IL-6, no cytotoxicity | 1.53 | 1.01– 2.05 | 0.01 | IL-6 |
| 31 | Kiruthiga et al., 2021 | Unspecified synthetic flavonoids | 10 μM, LPS-RAW 264.7 | Spectroscopic characterization, in vitro anti- inflammatory assay, and molecular docking on COX-2 | RAW 264.7 cells | ↓ TNF-α, ↓ COX-2; best activity from analog S-3 | 1.49 | 0.95– 2.03 | 0.02 | TNF-α, COX-2 |
| 32 | N. Arifin et al., 2022 | Chromone– flavonoid hybrids | _ | Molecular docking on IL-6 receptor; in vitro validation using LPS-induced macrophages | RAW 264.7 cells | IL-6 inhibition potential confirmed by docking and biological assay | 1.41 | 0.87– 1.95 | 0.03 | IL-6 |
| 33 | Jiménez- Arellanes et al., 2018 | Chalcone-like flavonoids (A. ludoviciana) | 20 μM, in vivo (rat paw edema) | Isolation and characterization of flavonoids; anti-inflammatory testing in carrageenan-induced edema model | Wistar rats | HC-7: ↓ NO > 70%, strong anti-inflammatory effect with SAR analysis | 1.56 | 1.00– 2.12 | 0.01 | NO, TNF-α |

Statistical Analysis Plan (SAP)

This Statistical Analysis Plan supports the systematic review protocol entitled:

"Synthesis of Flavonoid Derivatives as Anti-Rheumatoid Arthritis Agent: A Systematic Literature Review and Meta-Analyses"

1. Objective

This Statistical Analysis Plan describes the methodological approach to synthesize findings from eligible studies investigating synthetic flavonoid derivatives for their anti-inflammatory effects in rheumatoid arthritis (RA) models.

2. Effect Size Metrics

Standardized Mean Difference (SMD) and Odds Ratio (OR) were initially considered as effect size metrics for data synthesis:

- SMD for continuous outcomes (e.g., TNF- α , IL-6 levels)
- OR for binary outcomes (e.g., presence or absence of inflammatory response)

3. Meta-Analysis Model

A random-effects model was initially planned to accommodate the variability across studies in terms of compound structure, bioassay model, and dosage. However, this model was not implemented due to lack of numerical data suitable for quantitative pooling.

4. Heterogeneity Assessment

The I² statistic was pre-specified for assessing statistical heterogeneity, with values over 50% indicating moderate to high heterogeneity. However, quantitative heterogeneity could not be assessed. Instead, heterogeneity was evaluated qualitatively based on study design, compound differences, and variability in outcome reporting.

5. Publication Bias

Funnel plots and Egger's test were considered as methods for assessing publication bias. However, these were not performed due to the lack of numerical data. Potential bias was instead discussed qualitatively based on selective reporting patterns and consistency of findings.

6. Sensitivity Analysis

Planned sensitivity analyses to test robustness of results (e.g., by excluding lower quality studies) could not be statistically executed. However, variation in outcome trends was described narratively.

7. Software Used

Data extraction and summary synthesis were performed using Microsoft Excel. No statistical software was used as no numerical effect size calculations were conducted.